EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Evommune, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$5.27+0.10 (+1.93%)

Close on Oct 19, 2026

Market cap: $190.43M
P/E (TTM): –
Dividend yield: –

Evommune, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Revenue	13	7.00
Research & Development	74	64
General & Administrative	20	13
Operating Expenses	94	77
Operating Income	-81	-70
Interest & Investment Income	3.32	3.24
Other Non-Operating Income	12	3.21
Asset Impairment Charges	0	0
Pretax Income	-69	-68
Income Tax Expense	0	0
Net Income incl. Noncontrolling Interests	-69	-67
Net Income	-69	-67
Net Income to Common	-69	-68
EPS (Basic)(per share)	-11.22	-45.29
EPS (Diluted)(per share)	-11.22	-45.29
Shares Outstanding (Basic, Weighted)(shares)	6.14	1.51
Shares Outstanding (Diluted, Weighted)(shares)	6.14	1.51
EBITDA	-80	-70

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -1018.9%
Net margin: -946.7%
Return on equity, FY2025: -224.6%

Financial strength

Current ratio: 11.68
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 343.3%

Valuation

P/E ratio: –
Price to sales: 19.04
Price to book: 0.69
Dividend yield: –